Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib and Enzalutamide in Advanced Prostate Cancer
NCT01885949Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2013
- Primary completion
- May 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivozanib in prostate cancer (PCa), sponsored by Massachusetts General Hospital. Primary endpoint: Progression Free Survival at 2 years. Started Sep 2013; status: terminated.
02
Drugs
tivozanib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01885949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01885949.